In the Healthcare Business, we will continue promoting sales expansion of DR products. Sales growth in the fiscal year ended March 31, 2013 was centered on Japan, but we project business expansion through BtoB also in Europe and the United States in the fiscal year ending March 31, 2014.
With regard to this point, we are planning to announce the launch of new sales channels in collaboration with partner companies in the near future.
We also aim to increase earnings through contribution from cost reductions based on production outsourcing for films implemented in the fiscal year ended March 31, 2013 together with expanding sales of CR devices as a set in emerging countries.
This business has been shifting steadily to a growth track since the year ended March 31, 2013 and we are anticipating the same trend to continue going forward.
With regard to this point, we are planning to announce the launch of new sales channels in collaboration with partner companies in the near future.
We also aim to increase earnings through contribution from cost reductions based on production outsourcing for films implemented in the fiscal year ended March 31, 2013 together with expanding sales of CR devices as a set in emerging countries.
This business has been shifting steadily to a growth track since the year ended March 31, 2013 and we are anticipating the same trend to continue going forward.